Clinical Trial Update: ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing dacomitinib to gefitinib in first-line advanced non-small cell lung cancer with EGFR-activating mutations; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Pfizer | Conditions: Non-small Cell Lung Cancer With EGFR-Activating Mutations | Phase 3 | Status: COMPLETED | Results posted: 2018-10-26